Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

14:44
10/09/16
10/09
14:44
10/09/16
14:44

Novartis reports Phase 3 data on LEE011 in breast cancer

Novartis announced that results from the pivotal Phase III MONALEESA-2 study show LEE011, or ribociclib, plus letrozole significantly extended progression-free survival compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer. The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44% over letrozole alone. The combination significantly improved PFS across all patient subgroups, regardless of disease characteristics or demographics. More than half of women with measurable disease taking LEE011 plus letrozole saw their tumor size shrink by at least 30% -- overall response rate in patients with measurable disease was 53% vs 37%. Most adverse events in the MONALEESA-2 trial were mild to moderate in severity, identified early through routine monitoring, and generally managed through dose interruption and reduction. The discontinuation rate due to adverse events in the MONALEESA-2 trial was 7.5% for LEE011 plus letrozole and 2.1% for letrozole alone. The most common grade 3/4 adverse events were as follows for LEE011 plus letrozole compared to letrozole alone: neutropenia 60% vs 1%, leukopenia 21% vs 1%, elevated alanine aminotransferase 9% vs 1%, lymphopenia 7% vs 1%, and elevated aspartate aminotransferase 6% vs 1%. Due to the significant extension of PFS and clinical benefit seen with LEE011, analysis of the primary endpoint in MONALEESA-2 was stopped early in May as recommended by the Independent Data Monitoring Committee. Follow up to measure overall survival is ongoing.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

DVN

Devon Energy

$31.17

0.69 (2.26%)

13:30
06/26/17
06/26
13:30
06/26/17
13:30
Options
Devon Energy draws a bullish longer-term option play »

Devon Energy draws a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

DAL

Delta Air Lines

$52.94

0.02 (0.04%)

13:26
06/26/17
06/26
13:26
06/26/17
13:26
Periodicals
Amtrak picks former Delta CEO Anderson as new CEO, WSJ reports »

Former Delta CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

13:25
06/26/17
06/26
13:25
06/26/17
13:25
General news
Treasury Action: shorter yields dipped slightly after the strong 2-year sale »

Treasury Action: shorter…

PDCE

PDC Energy

$44.72

2.21 (5.20%)

13:22
06/26/17
06/26
13:22
06/26/17
13:22
Hot Stocks
Department of Justice, Colorado file civil complaint against PDC Energy »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

13:20
06/26/17
06/26
13:20
06/26/17
13:20
Options
Call buyer opens a notable new position in 20th Century Fox »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

, MSFT

Microsoft

$71.21

0.95 (1.35%)

13:19
06/26/17
06/26
13:19
06/26/17
13:19
Hot Stocks
Facebook, Twitter, Microsoft, YouTube form global forum to counter terrorism »

Facebook (FB), Microsoft…

FB

Facebook

$155.07

1.67 (1.09%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

TWTR

Twitter

$18.35

-0.155 (-0.84%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

$NSD

NASDAQ Market Internals

13:17
06/26/17
06/26
13:17
06/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/26/17
06/26
13:16
06/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

, SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Technical Analysis
Technical View: S&P 500 chart view at mid-session »

The small bearish price…

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$13.68

-0.12 (-0.87%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Options
Goldcorp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KR

Kroger

$22.58

-0.02 (-0.09%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Hot Stocks
Kroger executive VP Schlotman acquires 2,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
06/26/17
06/26
13:15
06/26/17
13:15
General news
Treasury's $26 B 2-year sale was well received, as expected »

Treasury's $26 B…

DB

Deutsche Bank

$16.89

0.25 (1.50%)

13:12
06/26/17
06/26
13:12
06/26/17
13:12
Periodicals
Deutsche Bank's chief U.S. economist LaVorgna steps down, Bloomberg reports »

Joe LaVorgna, a chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

WDC

Western Digital

$93.34

3.09 (3.42%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

13:11
06/26/17
06/26
13:11
06/26/17
13:11
Periodicals
Toshiba near sale of memory chip unit to consortium, Nikkei reports »

Toshiba (TOSYY) could…

WDC

Western Digital

$93.34

3.09 (3.42%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$146.28

0.65 (0.45%)

13:09
06/26/17
06/26
13:09
06/26/17
13:09
Hot Stocks
Apple CEO: 'Inspired' by Indian PM Modi's vision »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZIXI

ZixCorp

$5.77

-0.06 (-1.03%)

13:05
06/26/17
06/26
13:05
06/26/17
13:05
Hot Stocks
Breaking Hot Stocks news story on ZixCorp »

ETF Managers reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$28.97

-0.29 (-0.99%)

12:58
06/26/17
06/26
12:58
06/26/17
12:58
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Novo Holdings cuts Reata…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

HSTM

HealthStream

$30.89

0.72 (2.39%)

12:57
06/26/17
06/26
12:57
06/26/17
12:57
Recommendations
HealthStream analyst commentary  »

HealthStream contract end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Treasury 2-year auction preview: the sale should see decent results »

Treasury 2-year auction…

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Breaking General news story  »

San Francisco Federal…

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

12:46
06/26/17
06/26
12:46
06/26/17
12:46
Hot Stocks
Amazon CEO: Excited to keep investing in India »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

12:43
06/26/17
06/26
12:43
06/26/17
12:43
Periodicals
EU to likely hit Google with record fine in antitrust case, Reuters says »

EU antitrust authorities…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NURO

NeuroMetrix

$2.95

0.06 (2.08%)

12:39
06/26/17
06/26
12:39
06/26/17
12:39
Hot Stocks
NeuroMetrix names Xuan Kong as Chief Data Scientist »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$17.41

-0.13 (-0.74%)

12:38
06/26/17
06/26
12:38
06/26/17
12:38
Periodicals
Snap taps Internet Association's Woodworth for public policy team, Recode says »

Recode's Tony Romm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

DEO

Diageo

$120.05

0.7915 (0.66%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Upgrade
Diageo rating change  »

Diageo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.